
    
      Patients who complete a 28-day cycle, may be eligible to continue receiving Aneustatâ„¢ (OMN54)
      in 4-week increments for up to 6 cycles (inclusive of cycle 1) if further treatment is judged
      to be of possible benefit; if patient has not experienced unacceptable toxicity; and no study
      withdrawal criteria has been met.
    
  